Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Juan Orlando Hernandez Seeks Dismissal of Honduras Charges After Trump Pardon 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
California ICE Detention Center Found to Have Inadequate Medical Care, Court Monitor Says 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
